01—Abstract
Summary
Summary of the 8-K filed August 11, 2025. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (Nasdaq: ROIV) reported financial results for the quarter ended June 30, 2025, in a press release attached as Exhibit 99.1 to this Form 8-K.
The company reported revenue of $2.2 milliona, compared with $8.0 million a year earlier, and a loss from continuing operations, net of tax, of $273.9 million, or $0.33 per share, versus income of $31.6 million in the prior-year period. Research and development expenses rose to $152.9 million from $120.5 million, and general and administrative expenses rose to $134.0 million from $99.9 million. The filing attributes the G&A increase mainly to a $34.2 million rise in share-based compensation tied to long-term equity incentive awards.
Non-GAAP loss from continuing operations was $170.1 millionb, compared with $107.1 million a year earlier. Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.5 billion at June 30, 2025, which it says supports cash runway into profitability. The company completed its $1.5 billion share repurchase program, including $208 million of repurchases in the quarter, and reduced outstanding shares by over 15% from March 31, 2024.
The board approved a new $500 millionc repurchase program in June 2025. The filing highlights several clinical and legal catalysts. The Phase 3 VALOR study of brepocitinib in dermatomyositis is expected to read out topline data in the second half of calendar 2025, with last patient last visit completed in July.
Other expected readouts include brepocitinib in cutaneous sarcoidosis in the second half of 2026 and in non-infectious uveitis in the first half of 2027. In the LNP litigation, a jury trial in the U.S. Moderna case is scheduled for March 2026.
02—Key points
Key Highlights
- Net loss from continuing operations of $273.9 million ($0.33 per share) for the quarter, compared with $31.6 million in the prior-year quarter; non-GAAP loss from continuing operations was $170.1 million.
- Revenue of $2.2 million, down from $8.0 million in the prior-year quarter.
- R&D expenses of $152.9 million, up from $120.5 million, driven by program costs of $19.8 million and personnel expenses of $11.0 million.
- G&A expenses of $134.0 million, up from $99.9 million, primarily due to a $34.2 million increase in share-based compensation.
- Cash, cash equivalents, restricted cash and marketable securities of $4.5 billion at June 30, 2025; the company says this supports cash runway into profitability.
- Completed the $1.5 billion share repurchase program ($208 million in the quarter) and approved a new $500 million program in June 2025.
- Key catalysts include VALOR Phase 3 topline data for brepocitinib in dermatomyositis in the second half of 2025 and a Moderna LNP jury trial scheduled for March 2026.
03—Questions
Frequently Asked Questions
What drove the swing from prior-year income to a loss in the quarter?
The filing shows a loss from continuing operations of $273.9 million, compared with $31.6 million a year earlier. The prior-year period included $89.1 million of income from discontinued operations (Dermavant) and a $110.4 million gain on the sale of Telavant net assets, which did not recur. Operating expenses also increased, with R&D up $32.4 million and G&A up $34.1 million.
How much cash does Roivant have, and what is it doing with capital?
Consolidated cash, cash equivalents, restricted cash and marketable securities were $4.5 billion at June 30, 2025. The company completed a $1.5 billion share repurchase program, including $208 million in the quarter, which reduced outstanding shares by over 15% from March 31, 2024. A new $500 million repurchase program was approved in June 2025.
What are the next major clinical milestones?
Priovant expects topline data from the Phase 3 VALOR study of brepocitinib in dermatomyositis in the second half of calendar 2025, with last patient last visit completed in July. Brepocitinib in cutaneous sarcoidosis is expected to read out in the second half of 2026, and in non-infectious uveitis in the first half of 2027. Immunovant expects batoclimab remission data in Graves' disease at the ATA Annual Meeting in September 2025.
What is the status of the LNP litigation?
The summary judgment phase is ongoing in the U.S. Moderna case, with a jury trial scheduled for March 2026. International proceedings continue, with first major hearings expected in the first half of calendar 2026. A judge's decision on the Markman hearing in the Pfizer/BioNTech case is pending.
04—Continue